Compare

Conmed/$CNMD

1D1W1M3M6MYTD1Y5YMAX

About Conmed

Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
Ticker
$CNMD
Sector
Health
Primary listing
NYSE
Employees
3,900
Headquarters
Largo, United States
Website
www.conmed.com

Conmed Metrics

BasicAdvanced
$1.4B
24.95
$1.84
0.93
$0.20
1.74%

What the Analysts think about Conmed

Analyst ratings (Buy, Hold, Sell) for Conmed stock.
Analyst projections of the future price of Conmed stock.

Bulls say / Bears say

CONMED delivered 6% organic constant-currency sales growth in the second quarter, with gains in both Orthopedic Surgery and General Surgery. Management reaffirmed 5%-6% organic growth for 2026, suggesting the core business is expanding despite the gastroenterology exit. (Business Wire, CONMED)
The main growth platforms still offer room to run. AirSeal gained compatibility with Intuitive’s 8 mm hex cannulas used on the da Vinci 5 platform, while international orthopaedic sales rose 10.8% in the second quarter. (Business Wire, Stock Analysis)
Profitability is improving alongside the operational recovery. CONMED raised its 2026 adjusted EPS guidance to $4.48-$4.60, and management says service levels have strengthened while back-orders have fallen to their lowest levels in years. (Stock Analysis, Business Wire)
Reported growth remains weak because the gastroenterology exit is masking the underlying improvement. Second-quarter sales rose only 0.3% year on year, while management cut the top end of its 2026 organic-growth range from 6.5% to 6%. (CONMED, Stock Analysis)
The balance sheet still limits flexibility. CONMED ended the second quarter with about $834 million of debt and $37 million of cash, while expected 2026 interest expense rose to roughly $33 million after refinancing. (StockTitan, Stock Analysis)
AirSeal faces a product-quality overhang at an important time for the growth story. The FDA lists an open Class II recall for an AirSeal access port because of potential overpressure alerts, and CONMED expanded the affected distribution to international units. (U.S. Food and Drug Administration)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.

Conmed Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Conmed Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Conmed News

AllArticlesVideos

CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

Business Wire1 month ago

CONMED Q2 Earnings Call Highlights

MarketBeat2 months ago

CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula

Business Wire3 months ago

Funds containing Conmed

AllUSDGBPEUR
Funds
Fund name
Fund size
$CNMD weighting
iShares S&P SmallCap 600$IDP6
$3.2B0.08%
iShares S&P Small Cap 600£ISP6
£2.4B0.08%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.05%
SPDR Russell 2000 US Small Cap£R2SC
£4.1B0.05%
iShares MSCI World Small Cap$WSML
$9B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.